drugset / Trial / NCT05333744

The Combination of Prednisone and Recombinant Human Thrombopoietin for Treatment of Immune Thrombocytopenia in Pregnancy

NCT05333744

Phase 2 Unknown 90 enrolled Peking University People's Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized, open-label study to compare the efficacy and safety of prednisone plus recombinant human thrombopoietin (rhTPO) compared to prednisone monotherapy for the treatment of immune thrombocytopenia in pregnancy

Timeline

Start
2021-06-01
Primary completion
2022-06-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant human thrombopoietin Protein / enzyme biologic 300 iu/kg Intramuscular
Background Prednisone Other / unclassified 5 mg Oral
Background Prednisone Other / unclassified 10 mg Oral